Press / Media  

 



4-14-10 Audio Interview with Cyplasin Biomedical Ltd.
(OTCBB: CPBM)


The CEO of Cyplasin Biomedical Ltd. (OTCBB: CPBM), Garth Likes, called into SmallCapVoice.com to discuss how Cyplasin stays focused on anti-viral therapies and a preventative vaccine in the Hepatitis C market. The Company is interested in talking to other pharmaceutical and biotechnology companies in an effort to license and partner the other indications derived from this core technology platform. Mr. Likes concludes, "By announcing this first deal related to several cancer targets, we hope to attract other strategic partners with interests in any or all of the potential therapeutic areas where this technology might be applied."
Subscribe to our Free Newsletter

To sign up and receive our newsletters, complete the form below and click submit.
We look forward to keeping you informed and up-to-date about our company

All fields marked * are required
Hepatitus C treatment Home | Company | Products | Investor Relations | Strategy | Press | Management | Related Resources | Privacy | Disclaimer | Contact
Content copyright 2010. C-Pharma. All rights reserved.